{"id":"gelox","rwe":[{"pmid":"37188610","year":"2023","title":"Temperature Monitoring of Two Different Thermal Boxes for the Transport of Biological Samples.","finding":"","journal":"Transplantation proceedings","studyType":"Clinical Study"},{"pmid":"35663228","year":"2022","title":"Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime.","finding":"","journal":"Molecular therapy oncolytics","studyType":"Clinical Study"},{"pmid":"30449214","year":"2019","title":"Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion.","finding":"","journal":"Expert review of anticancer therapy","studyType":"Clinical Study"},{"pmid":"29760798","year":"2018","title":"A Multicenter Retrospective Comparison of Sequential versus Sandwich Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.","finding":"","journal":"Journal of Cancer","studyType":"Clinical Study"},{"pmid":"29712887","year":"2018","title":"Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.","finding":"","journal":"Medical science monitor : international medical journal of experimental and clinical research","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Sun Yat-sen University","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["gemcitabine","oxaliplatin","asparaginase","pegaspargase"],"company":"Sun Yat-sen University","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GELOX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:00:07.957459+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:00:13.404328+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GELOX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:00:13.754615+00:00"}},"allNames":["gelox"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"As a small molecule compound, Gelox is likely designed to bind to a specific protein or receptor, altering its function or activity to produce a therapeutic effect. However, without more information on its target or drug class, it's impossible to provide a detailed technical explanation of its mechanism of action."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=gelox","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=gelox","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:27:26.598108","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:00:15.760097+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"gelox","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02080234","phase":"PHASE2","title":"Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-03","conditions":["Lymphoma, Extranodal NK-T-Cell"],"enrollment":40,"completionDate":"2017-03"},{"nctId":"NCT02229682","phase":"PHASE2","title":"Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-10","conditions":["Lymphoma,","Non-Hodgkin Lymphoma,","Extranodal NK/T-cell Lymphoma,Nasal-type,"],"enrollment":40,"completionDate":"2019-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Sun Yat-sen University","relationship":"Original Developer"}],"publicationCount":18,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Sun Yat-sen University","recentPublications":[{"date":"2023 Jul-Aug","pmid":"37188610","title":"Temperature Monitoring of Two Different Thermal Boxes for the Transport of Biological Samples.","journal":"Transplantation proceedings"},{"date":"2022 Jun 16","pmid":"35663228","title":"Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime.","journal":"Molecular therapy oncolytics"},{"date":"2019 Jan","pmid":"30449214","title":"Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion.","journal":"Expert review of anticancer therapy"},{"date":"2018","pmid":"29760798","title":"A Multicenter Retrospective Comparison of Sequential versus Sandwich Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.","journal":"Journal of Cancer"},{"date":"2018 May 1","pmid":"29712887","title":"Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.","journal":"Medical science monitor : international medical journal of experimental and clinical research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"GELOX","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:00:15.760097+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}